 Fabry disease is an inherited genetic disorder caused by mutations in the alpha-galactosidase A gene. This results in decreased levels of the enzyme alpha-galactosidase A, leading to the accumulation of certain fatty substances called globotryosilceramide, GB3, and lyso-GB3 in the kidneys. These fatty substances build up in the kidneys, causing damage to the cells and ultimately resulting in kidney failure. enzyme replacement therapy and pharmacological chaperones are currently used as treatments for Fabry disease. Recent research suggests that the enzyme can also be taken up by specific proteins in the kidney, such as megalin and sordilin, which helps clear GB3 and lyso-GB3 from the kidneys. This process can help reduce the amount of damage done to the kidneys and improve their function. Additionally, Fabry patients have been found to be more susceptible to complications during the COVID-19 pandemic, including acute kidney injury and requiring renal replacement therapy. This article was authored by Ernon Tremarky. We are article.tv, links in the description below.